Vitiligo
Conditions
Brief summary
study the cutaneous expression of PGF2α in vitiligo patients and compare it with normal control subjects.
Detailed description
Measurement of tissue levels of PGF2α in vitiligo patients and compare them with healthy controls.
Interventions
OTHERSkin biopsy
Two skin biopsies (lesional and non-lesional) will be taken from every patient. Also a skin biopsy will be taken from each control subject.
Sponsors
Cairo University
Study design
Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
DIAGNOSTIC
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
Yes
Inclusion criteria
* Patients with non-segmental vitiligo. * Both sexes. * Age \< 18 years old. * New cases or cases not receiving any medications for at least 3 months ago.
Exclusion criteria
* Age: Patients \< 18 years. * Segmental or universal vitiligo. * Pregnant and lactating females.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Measurement of tissue levels of PGF2α in vitiligo patients and compare them with healthy controls. | 6 months | Measurement of tissue levels of PGF2α in vitiligo patients and compare them with healthy controls to study and verify the hypothesis of involvement of PGF2α in the pathogenesis of vitiligo.• Skin biopsy for assessment of tissue levels of the PGF2α will be taken from both lesional and non lesional skin of patients of vitiligo and from normal skin of healthy controls. All skin biopsies are from non-sun exposed sites. |
Outcome results
None listed